UPDATE: Jefferies Upgrades Sabra Health Care REIT on Attractive Entry Point

Loading...
Loading...
In a report published Wednesday, Jefferies analyst Omotayo Okusanya upgraded the rating on
Sabra Health Care REITSBRA
from Hold to Buy, but lowered the price target from $27.00 to $26.00. In the report, Jefferies noted, “We had previously downgraded SBRA stock from Buy to Hold back in April on concerns of valuation following a 250% run-up in the stock since 2011. However, with the stock now down over 26% since May, shares appear oversold, offering an attractive entry point. While a rising cost of capital and recent lack of deal flow are concerns, recent pipeline agreements suggest new transactions are imminent. Upgrade to Buy but lower PT to $26.” Sabra Health Care REIT closed on Tuesday at $22.49.
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorUpgradesAnalyst RatingsJefferiesOmotayo Okusanya
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...